相似文献
1
Laboratory and clinical characteristics of attenuated strains of influenza virus.
Bull World Health Organ. 1969;41(3):589-94.
2
Evaluation of influenza virus mutants for possible use in a live virus vaccine.
Bull World Health Organ. 1969;41(3):599-606.
3
Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
Vaccine. 2006 Mar 10;24(11):1966-74. doi: 10.1016/j.vaccine.2005.10.051. Epub 2005 Nov 8.
4
The efficacy of live influenza vaccines.
Bull World Health Organ. 1969;41(3):585-8.
5
Interfering activity of virulent and attenuated influenza virus strains.
Acta Virol. 1976 Jun;20(3):189-95.
6
Phenotypic and genetic analyses of the heterogeneous population present in the cold-adapted master donor strain: A/Leningrad/134/17/57 (H2N2).
Virus Res. 2004 Jun 15;102(2):165-76. doi: 10.1016/j.virusres.2004.01.026.
7
Peculiarities of obtaining and characterization of a cold-adapted A/PR/8/34 influenza virus variant.
Acta Virol. 1984 Jan;28(1):19-25.
8
Attenuation of lentogenic Newcastle disease virus strain B-1 by cold adaptation.
Avian Dis. 1996 Jul-Sep;40(3):605-12.
9
Location of ts defects in the genome of cold-adapted recombinant influenza A virus vaccine strains.
Acta Virol. 1984 May;28(3):204-11.
10
In vitro markers for measuring residual virulence for men of live attenuated influenza viruses.
Dev Biol Stand. 1977;39:33-40.
引用本文的文献
1
Research Progress of Universal Influenza Vaccine.
Vaccines (Basel). 2025 Aug 15;13(8):863. doi: 10.3390/vaccines13080863.
2
Development of Cross-Reactive Live Attenuated Influenza Vaccine Candidates against Both Lineages of Influenza B Virus.
Vaccines (Basel). 2024 Jan 18;12(1):95. doi: 10.3390/vaccines12010095.
3
[Health Technology Assessment (HTA) of the introduction of influenza vaccination for Italian children with Fluenz Tetra].
J Prev Med Hyg. 2021 Sep 10;62(2 Suppl 1):E1-E118. doi: 10.15167/2421-4248/jpmh2021.62.2s1. eCollection 2021 Jun.
4
Emerging Role of Mucosal Vaccine in Preventing Infection with Avian Influenza A Viruses.
Viruses. 2020 Aug 7;12(8):862. doi: 10.3390/v12080862.
5
How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions.
Influenza Other Respir Viruses. 2019 Sep;13(5):429-437. doi: 10.1111/irv.12664. Epub 2019 Jun 21.
6
Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine.
J Virol. 2018 Oct 12;92(21). doi: 10.1128/JVI.01025-18. Print 2018 Nov 1.
7
Development of an Alternative Modified Live Influenza B Virus Vaccine.
J Virol. 2017 May 26;91(12). doi: 10.1128/JVI.00056-17. Print 2017 Jun 15.
8
Development of a stable liquid formulation of live attenuated influenza vaccine.
Vaccine. 2016 Jul 12;34(32):3676-83. doi: 10.1016/j.vaccine.2016.04.074. Epub 2016 May 4.
9
Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium.
J Virol. 2012 Nov;86(21):11725-34. doi: 10.1128/JVI.01477-12. Epub 2012 Aug 22.
10
Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness.
PLoS One. 2011;6(10):e24057. doi: 10.1371/journal.pone.0024057. Epub 2011 Oct 13.
本文引用的文献
1
Adaptation and growth characteristics of influenza virus at 25 degrees c.
Nature. 1967 Feb 11;213(5076):612-4. doi: 10.1038/213612a0.
2
Biologic and immunologic characteristics of cold-adapted influenza virus.
J Immunol. 1969 Mar;102(3):728-32.
3
Differentiation of temperature variants of influenza A2 viruses on the basis of plaque formation.
J Virol. 1968 May;2(5):456-60. doi: 10.1128/JVI.2.5.456-460.1968.
4
Plaque formation of influenza virus at 25 degrees C.
Nature. 1968 Aug 10;219(5154):645-6. doi: 10.1038/219645a0.
Zotero 插件